Breast Cancer Clinical Trial

A Trial of RSL Versus WL for Malignant Breast Disease

Summary

The purpose of this randomized trial is to determine the superiority of utilizing radioactive seed localization (RSL) over wire-guided localization (WL) for palpable or non-palpable malignant lesions in patients undergoing breast conservation surgery (BCS).

View Full Description

Full Description

Consented and eligible subjects will be randomized to either radioactive seed localization or wire localization and stratified by surgeon and invasive versus DCIS prior to localization. Subjects on both arms will undergo breast conservation surgery including surgical specimen removal. Specimens will be grossed according to standard of care procedures. Localization, breast conservation surgery, and post-operative appointments will follow standard of care guidelines. Surveys will be administered according to the study calendar to the radiologist, surgeon, pathologist, and subject for data collection.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Female
20 to 99 years of age
Breast lesion necessitating image-guided excision
Unifocal disease
Breast-conservation candidate
Biopsy-proven malignant breast lesion including by not limited to invasive ductal carcinoma, invasive lobular carcinoma, and ductal carcinoma in situ
Signed written informed consent document by the subject and/or a LAR

Exclusion Criteria:

Male
Multifocal or multicentric disease
Receiving neoadjuvant chemotherapy
Pregnant or breastfeeding
Locally advanced disease
Breast conservation contraindication such as inability to receive whole breast radiation therapy, inability to tolerate localization procedure, inability to lay flat or prone for radiation, and undesirable tumor to breast ratio
Prior breast cancer on ipsilateral side
Unable or unwilling to adhere to post-localization instructions (e.g. timely seed removal)

Study is for people with:

Breast Cancer

Estimated Enrollment:

400

Study ID:

NCT02522468

Recruitment Status:

Completed

Sponsor:

Wake Forest University Health Sciences

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Levine Cancer Institute
Charlotte North Carolina, 28204, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

400

Study ID:

NCT02522468

Recruitment Status:

Completed

Sponsor:


Wake Forest University Health Sciences

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider